14 results
ARS
2022 FY
PNT
POINT Biopharma Global Inc.
1 May 23
Annual report to shareholders
1:52pm
relies, and expects to continue to relying, on third parties to package, label, store and distribute their investigational product candidates
8-K
EX-1.1
PNT
POINT Biopharma Global Inc.
14 Sep 22
POINT Biopharma Prices Public Offering of Common Stock
4:14pm
or necessary to make the statements therein not misleading. As of the Time of Sale (as defined below), neither (A) the Time of Sale Disclosure Package … (as defined below) nor (B) any issuer free writing prospectus (as defined below), when considered together with the Time of Sale Disclosure Package
DEF 14A
1p322yt5deoib0o
28 Apr 22
Definitive proxy
8:36am
424B3
1z9oed
5 Aug 21
Prospectus supplement
4:26pm
S-4/A
EX-10.12
by6mcit2t mba
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
EX-10.19
46s fynqh7
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4
EX-10.12
wou1swemymp5nxgu5
22 Mar 21
Registration of securities issued in business combination transactions
9:52pm
8-K
EX-1.1
aw2sv
10 Jul 20
Therapeutics Acquisition Corp., Sponsored by RA Capital Management, L.P., Announces Pricing of Upsized $118 Million Initial Public Offering
5:17pm
S-1
EX-1.1
uvzbvtmk4ep056s
15 Jun 20
IPO registration
5:28pm
- Prev
- 1
- Next